MCA
ABBV icon

Morris Capital Advisors’s AbbVie ABBV Stock Holding History

Morris Capital Advisors’s Portfolio ABBV Stock Details ABBV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		$3.16M Sell
23,565
-249
-1% -$35.7K 2.98% 12
2022
Q2 		$3.65M Buy
23,814
+176
+0.7% +$26.9K 3.25% 7
2022
Q1 		$3.83M Sell
23,638
-544
-2% -$79K 2.97% 12
2021
Q4 		$3.27M Sell
24,182
-1,272
-5% -$150K 2.41% 16
2021
Q3 		$2.75M Sell
25,454
-1,065
-4% -$122K 2.16% 20
2021
Q2 		$2.99M Sell
26,519
-38
-0.1% -$4.28K 2.26% 20
2021
Q1 		$2.87M Sell
26,557
-821
-3% -$87.8K 2.33% 20
2020
Q4 		$2.93M Buy
27,378
+2,443
+10% +$235K 2.41% 17
2020
Q3 		$2.18M Sell
24,935
-1,535
-6% -$145K 1.93% 23
2020
Q2 		$2.6M Buy
26,470
+1,463
+6% +$129K 2.35% 15
2020
Q1 		$1.91M Buy
25,007
+1,740
+7% +$148K 2.04% 19
2019
Q4 		$2.06M Sell
23,267
-5,272
-18% -$438K 1.72% 28
2019
Q3 		$2.16M Sell
28,539
-2,376
-8% -$163K 1.9% 24
2019
Q2 		$2.25M Sell
30,915
-6,079
-16% -$478K 1.87% 26
2019
Q1 		$2.98M Sell
36,994
-455
-1% -$37.2K 2.33% 19
2018
Q4 		$3.45M Sell
37,449
-2,389
-6% -$210K 2.94% 14
2018
Q3 		$3.77M Sell
39,838
-473
-1% -$44.9K 2.52% 19
2018
Q2 		$3.73M Buy
40,311
+17,716
+78% +$1.73M 2.62% 18
2018
Q1 		$2.14M Sell
22,595
-61
-0.3% -$6.7K 1.42% 30
2017
Q4 		$2.19M Sell
22,656
-737
-3% -$69.5K 1.43% 30
2017
Q3 		$2.08M Sell
23,393
-92
-0.4% -$7K 1.39% 30
2017
Q2 		$1.7M Sell
23,485
-893
-4% -$60K 1.2% 30
2017
Q1 		$1.59M Sell
24,378
-8,241
-25% -$518K 1.15% 31
2016
Q4 		$2.04M Sell
32,619
-5,639
-15% -$344K 1.42% 30
2016
Q3 		$2.41M Sell
38,258
-3,747
-9% -$243K 1.5% 30
2016
Q2 		$2.6M Buy
42,005
+5,847
+16% +$356K 1.54% 30
2016
Q1 		$2.06M Buy
36,158
+990
+3% +$55.2K 1.4% 31
2015
Q4 		$2.08M Buy
+35,168
New +$2.03M 1.45% 29

Other funds holding ABBV

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Morris Capital Advisors's ABBV Position: Q3 2022 in Review

Morris Capital Advisors reduced its AbbVie (ABBV) stake by 1% in Q3 2022, selling an estimated $35.7K and leaving 23,565 shares worth $3.16M. The position accounts for 2.98% of the portfolio, ranked #12.

Morris Capital Advisors first reported a position in ABBV in Q4 2015 and has held it in 28 quarters since. The position peaked at $3.83M in Q1 2022. 2,968 funds tracked by Wall St. Rank hold ABBV as of Q3 2022.

  • Morris Capital Advisors held 23,565 shares of AbbVie worth $3.16M as of Q3 2022.
  • Morris Capital Advisors sold 249 AbbVie shares in Q3 2022, an estimated $35.7K.
  • AbbVie made up 2.98% of Morris Capital Advisors's portfolio in Q3 2022, its #12 holding.
  • Morris Capital Advisors first reported a position in AbbVie in Q4 2015 and has held it in 28 quarters since.
  • Morris Capital Advisors's AbbVie position peaked at $3.83M in Q1 2022.
  • 2,968 funds tracked by Wall St. Rank held AbbVie as of Q3 2022.

Based on Morris Capital Advisors's 13F filing for Q3 2022, filed 26 Oct 2022.